Identifying Plasma Proteins for Hypertrophic Cardiomyopathy Penetrance and Severity in Pathogenic Variant Carriers and Noncarriers
BACKGROUND: Hypertrophic cardiomyopathy (HCM) is a clinically variable disease in onset and progression. Pathogenic MYBPC3 variants account for a substantial proportion of HCM diagnoses. OBJECTIVES: This study sought to identify protein biomarkers associated with HCM penetrance and severity. METHODS: Olink-assayed plasma proteins of 144 pathogenic MYBPC3 variant carriers were evaluated for associations with HCM severity based on diagnostic criteria (unaffected, mildly, or severely affected). Identified proteins were replicated in the UK Biobank considering time to onset of HCM (67 cases), cardiomyopathy (156 cases), and associations with left ventricular maximum wall thickness (6,492 participants). After prioritizing proteins on cardiac tissue expression and druggability, we examined disease penetrance through associations with heart failure (HF) and arrhythmic outcomes in 272 UK Biobank participants with known pathogenic HCM variants free of cardiomyopathy at proteomics assessment. RESULTS: Among pathogenic MYBPC3 variant carriers, we identified 27 proteins associated with HCM severity, of which 22 replicated in the UK Biobank. Six proteins were prioritized (N-terminal pro-B-type natriuretic peptide [NT-proBNP], growth/differentiation factor [GDF]-15, fibroblast growth factor [FGF]-23, adrenomedullin [ADM], renin [REN], and neural cell adhesion molecule 1 [NCAM1]), of which 5 associated with disease penetrance in pathogenic variant carriers: NT-proBNP and REN associated with increased HF and arrhythmic risk, GDF-15 and FGF-23 with HF risk, and NCAM1 with arrhythmic risk. CONCLUSIONS: Through the integration of proteomic analyses in both clinical and general population cohorts, we replicated and prioritized 6 proteins associated with HCM penetrance and severity. These findings highlight potential plasma-based markers for diagnosis and disease monitoring, as well as promising targets for future therapeutic development.
Authors
- Karin Y. van Spaendonck‐Zwarts (ORCID: https://orcid.org/0000-0003-0597-0404)
- Jolanda van der Velden (ORCID: https://orcid.org/0000-0001-5224-5788)
- Connie R. Bezzina (ORCID: https://orcid.org/0000-0002-0633-3514)
- Bram Ruijsink (ORCID: https://orcid.org/0000-0001-8313-5709)
- Amand Floriaan Schmidt (ORCID: https://orcid.org/0000-0003-1327-0424)
- Annette F. Baas (ORCID: https://orcid.org/0000-0002-0335-9452)
- Dennis Dooijes (ORCID: https://orcid.org/0000-0003-0312-5354)
- Folkert Wouter Asselbergs (ORCID: https://orcid.org/0000-0002-1692-8669)
- Ahmad S. Amin (ORCID: https://orcid.org/0000-0002-1600-7907)
- Jan D.H. Jongbloed (ORCID: https://orcid.org/0000-0003-0663-404X)
- Ronald H. Lekanne Deprez (ORCID: https://orcid.org/0000-0003-4687-0186)
- Saskia N. van der Crabben (ORCID: https://orcid.org/0000-0001-8619-1511)
- Diederik W.D. Kuster (ORCID: https://orcid.org/0000-0003-1498-6862)
- J. Peter van Tintelen (ORCID: https://orcid.org/0000-0003-3854-6749)
- Moniek G.P.J. Cox (ORCID: https://orcid.org/0000-0003-2825-8428)
- Anneline S.J.M. te Riele (ORCID: https://orcid.org/0000-0002-4694-4790)
- Fahima Hassanzada (ORCID: https://orcid.org/0009-0004-3987-9507)
- M. Jansen (ORCID: https://orcid.org/0000-0002-0896-4440)
- Marion van Vugt (ORCID: https://orcid.org/0000-0002-6634-1989)
Institutions
- University Medical Center Groningen (NL)
- King's College London (GB)
- Utrecht University (NL)
- University Medical Center Utrecht (NL)
- British Heart Foundation (GB)
- Amsterdam Neuroscience (NL)
- UCL Biomedical Research Centre (GB)
- ERN GUARD-Heart (NL)
- Amsterdam University Medical Centers (NL)
- Amsterdam Cardiovascular Sciences (NL)
- University College London (GB)
- Vrije Universiteit Amsterdam (NL)
- University of Amsterdam (NL)
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
Publication Details
- Journal
- JACC Advances
- Published
- 2026-11-17
- DOI
- https://doi.org/10.1016/j.jacadv.2026.103457
- Primary Topic
- Cardiomyopathy and Myosin Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bristol-Myers Squibb
- Government of the United Kingdom
- UK Research and Innovation
- Dutch Cardiovascular Alliance
- National Institute for Health and Care Research
- British Heart Foundation
- University College London
- ZonMw
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek
- Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers
- UCLH Biomedical Research Centre
- HORIZON EUROPE European Innovation Council